Which are the vaccinated who can still get seriously ill with Covid

Analyzing the medical records of 152 patients vaccinated with two doses and hospitalized with COVID-19, an Israeli research team led by scientists from the “Samson Assuta Ashdod” University Hospital has compiled a list of the characteristics most associated with the severe form of infection despite vaccination.

Turn on notifications to receive updates on

Like any other vaccine, even those against the coronavirus SARS-CoV-2 do not guarantee aeffectiveness al 100 percent, despite being very high. This means that a small minority of people, even if fully vaccinated, are still at risk of developing serious form e potentially lethal of the COVID-19. It should be borne in mind that at present, in the United States, 99 percent of deaths from the infection occur among not vaccinated; this gives a good idea of ​​how effective i Covid vaccines. It is no coincidence that the new American president Joe Biden stated that the pandemic is now among the unvaccinated. As indicated, however, even some vaccinated subjects are potentially exposed to the risk of serious COVID-19, for this reason an Israeli research team wanted to understand what are the characteristics that identify people at risk.

The investigation was conducted by a group led by scientists from the “Samson Assuta Ashdod” University Hospital, who collaborated closely with colleagues from the Division of Microbiology and Infectious Diseases of the Hadassah Hebrew University, of the Faculty of Medicine of the University of Jerusalem, the Sackler Faculty of Medicine of Tel Aviv University, the Shaare Zedek Medical Center and other institutes in the Middle Eastern country. Scientists, coordinated by Professor Tal Brosh-Nissimov, came to their conclusions after conducting one retrospective multicenter cohort study which involved patients hospitalized with COVID-19 in 17 Israeli hospitals. Everyone had been fully vaccinated (second dose for at least 7 days) with the vaccine BNT162b2/Tozinameran (commercial name Comirnaty) developed by the American pharmaceutical giant Pfizer in collaboration with the German biotechnology company BioNTech. In Israel, virtually all of the vaccinated population (58.2 percent of the total) received the messenger RNA vaccine.

In total they were involved in the study 152 patients, mainly males and with an average age of 71 years. One of the characteristics that united them was the high rate of comorbilità. Among them there were hypertension (detected in 108, 71 percent); diabetes (detected in 73, 48 percent); congestive heart failure (detected in 41, 27 percent); chronic kidney disease e pulmonary (detected in 37, 24 percent for each); dementia (detected in 29, 19 percent of the total) e cancer (detected in 36, 24 percent of the total). Only six of the 152 patients they did not show comorbidities, or 4 percent of the cohort. Interestingly, in sixty (40 percent) were immunocompromised patients due to medications and other conditions, therefore they may have responded poorly or not at all to the administration of the vaccine. The researchers point out that patients with less neutralizing antibodies (IgG immunoglobulins) against proteina S O Spike of the SARS-CoV-2 coronavirus had a higher risk, however the difference did not reach “statistical significance”, as for those receiving anti-CD20 treatments. The survey revealed that for 38 of the patients involved one was detected poor prognosis, with a mortality rate of 22 percent (34 of 152 patients died)

Because those who do not vaccinate against Covid 19 are also a problem for those who have been vaccinated

Scientists still cannot explain whether these vaccinated people ended up in hospital for other diseases they previously had and if the infection was a coincidence, even bearing in mind that a third of the cohort did not have symptoms similar to COVID-19. However, since a small minority still seems to run this risk, further analyzes on cohorts of this type could detect the most vulnerable segments of the population despite the vaccine, to be protected with ad hoc guidelines. According to Professor Brosh-Nissimov and colleagues, these patients could also be referred to as a priority for the third dose, of which we talk more and more insistently starting from next autumn. The details of the research “BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel” have been published in the specialized scientific journal Clinical Microbiology and Infection (CMI).

window._fpcmp.push(function(gdpr)
{
!function(f,b,e,v,n,t,s) {if(f.fbq)return;n=f.fbq=function(){n.callMethod?
n.callMethod.apply(n,arguments):n.queue.push(arguments)};
if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version=’2.0′;
n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];
s.parentNode.insertBefore(t,s)}(window, document,’script’,
‘https://connect.facebook.net/en_US/fbevents.js’);
fbq(‘init’, ‘2062554930705272’);
fbq(‘track’, ‘PageView’);
//fbq(‘track’, ‘ViewContent’);
//send custom checkpoints event
(function () {
var checkPoints = [10, 20, 40, 60, 90, 120, 180, 240, 300].sort(function(a, b) {
return a – b;
}); //seconds
var checkPointIndex = 0;
var f = function(){
var data = {
instant: checkPoints[checkPointIndex]
};
console.log(“[FB PIXEL] send custom event ViewContentCheckPoint “, data, ” on account ” ,”2062554930705272″ , ” currentTime in seconds “,
new Date().getTime() / 1000);
fbq(‘trackCustom’, ‘ViewContentCheckPoint’, data);
checkPointIndex++;
if(checkPointIndex < checkPoints.length) {
setTimeout(f, (checkPoints[checkPointIndex] – checkPoints[checkPointIndex-1]) * 1000)
}
};
if(checkPoints.length){
setTimeout(f, checkPoints[checkPointIndex] * 1000)
}

})();
});

Disclaimer: If you need to update/edit/remove this news or article then please contact our support team Learn more

Leave a Reply